KR20240000537A - 항-tslp 항체 조성물 및 이의 용도 - Google Patents

항-tslp 항체 조성물 및 이의 용도 Download PDF

Info

Publication number
KR20240000537A
KR20240000537A KR1020237039567A KR20237039567A KR20240000537A KR 20240000537 A KR20240000537 A KR 20240000537A KR 1020237039567 A KR1020237039567 A KR 1020237039567A KR 20237039567 A KR20237039567 A KR 20237039567A KR 20240000537 A KR20240000537 A KR 20240000537A
Authority
KR
South Korea
Prior art keywords
composition
tezepelumab
seq
derivative
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237039567A
Other languages
English (en)
Korean (ko)
Inventor
하오 장
알라 폴로조바
켈리 피츠패트릭
크리스틴 아브람스
동 샹
마리사 주버트
Original Assignee
암젠 인크
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 암젠 인크 filed Critical 암젠 인크
Publication of KR20240000537A publication Critical patent/KR20240000537A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020237039567A 2021-04-23 2022-04-22 항-tslp 항체 조성물 및 이의 용도 Pending KR20240000537A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163178938P 2021-04-23 2021-04-23
US63/178,938 2021-04-23
PCT/US2022/025994 WO2022226339A1 (en) 2021-04-23 2022-04-22 Anti-tslp antibody compositions and uses thereof

Publications (1)

Publication Number Publication Date
KR20240000537A true KR20240000537A (ko) 2024-01-02

Family

ID=81597810

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237039567A Pending KR20240000537A (ko) 2021-04-23 2022-04-22 항-tslp 항체 조성물 및 이의 용도

Country Status (19)

Country Link
US (1) US20240190951A1 (https=)
EP (1) EP4326766A1 (https=)
JP (1) JP2024517418A (https=)
KR (1) KR20240000537A (https=)
CN (1) CN117203233A (https=)
AR (1) AR125408A1 (https=)
AU (1) AU2022262421A1 (https=)
BR (1) BR112023021867A2 (https=)
CA (1) CA3216655A1 (https=)
CL (1) CL2023003155A1 (https=)
CO (1) CO2023014181A2 (https=)
CR (1) CR20230531A (https=)
IL (1) IL307540A (https=)
JO (1) JOP20230265A1 (https=)
MX (1) MX2023012363A (https=)
PE (1) PE20240068A1 (https=)
TW (1) TW202308690A (https=)
UY (1) UY39736A (https=)
WO (1) WO2022226339A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12110324B2 (en) 2022-07-22 2024-10-08 Flagship Pioneering Innovations Vi, Llc Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP)
TW202448501A (zh) 2023-02-02 2024-12-16 美商麥迪紐有限責任公司 用抗ｔｓｌｐ抗體治療慢性鼻竇炎
IL324470A (en) 2023-05-18 2026-01-01 Medimmune Llc Treatment of corticosteroid-dependent asthma using anti-TSLP antibody
WO2025147632A1 (en) 2024-01-05 2025-07-10 Medimmune, Llc Treatment of chronic obstructive pulmonary disease with anti-tslp antibody
WO2025221247A1 (en) 2024-04-17 2025-10-23 Amgen Inc. Treatment of eosinophilic esophagitis with anti-tslp antibody

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
ATE135397T1 (de) 1988-09-23 1996-03-15 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
US8359965B2 (en) 2007-09-17 2013-01-29 Oxford J Craig Apparatus and method for broad spectrum radiation attenuation
CN102281901A (zh) * 2008-11-20 2011-12-14 弗·哈夫曼-拉罗切有限公司 治疗性蛋白质制剂
WO2012007495A1 (en) 2010-07-15 2012-01-19 F. Hoffmann-La Roche Ag Antibodies specifically binding to human tslpr and methods of use
AT510032B1 (de) 2010-11-30 2012-01-15 Steiner Erwin Ing Montageeinrichtung für fassadenelemente
TWI593705B (zh) * 2011-12-28 2017-08-01 Chugai Pharmaceutical Co Ltd Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient
US9100245B1 (en) 2012-02-08 2015-08-04 Amazon Technologies, Inc. Identifying protected media files
WO2014031718A1 (en) * 2012-08-23 2014-02-27 Merck Sharp & Dohme Corp. Stable formulations of antibodies to tslp
US9306926B2 (en) 2013-03-15 2016-04-05 Brian A. Truong User authentication using unique hidden identifiers
WO2015116315A1 (en) 2014-01-29 2015-08-06 Amgen Inc. Overexpression of n-glycosylation pathway regulators to modulate glycosylation of recombinant proteins
FI3218005T3 (fi) * 2014-11-12 2023-03-31 Seagen Inc Glykaanin kanssa vuorovaikutteisia yhdisteitä ja käyttömenetelmiä
KR20170123315A (ko) * 2015-03-11 2017-11-07 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 Tslp 결합 단백질
KR102666879B1 (ko) * 2017-04-12 2024-05-23 암젠 인크 항-tslp 항체를 이용한 천식의 치료
JP7200134B2 (ja) 2017-06-08 2023-01-06 アムジエン・インコーポレーテツド トルク駆動式薬物送達デバイス
ES2978396T3 (es) * 2017-08-01 2024-09-11 Amgen Inc Sistemas y métodos para la preparación en tiempo real de una muestra de polipéptidos para el análisis por espectrometría de masas
MA50557A (fr) 2017-11-10 2020-09-16 Amgen Inc Pistons pour dispositifs d'administration de médicament
EP4321870B1 (en) 2018-03-13 2025-07-30 Amgen Inc. Methods for the preparation of trypsin-resistant polypeptides for mass spectrometric analysis
TW202541859A (zh) 2018-10-15 2025-11-01 美商安進公司 具有阻尼機構之藥物遞送裝置及自動注射器
WO2020081480A1 (en) 2018-10-15 2020-04-23 Amgen Inc. Platform assembly process for drug delivery device
JP7562563B2 (ja) 2019-04-30 2024-10-07 アムジエン・インコーポレーテツド バイオ医薬品生産における細胞株選択のためのデータ駆動予測モデリング
AU2020288652A1 (en) 2019-06-05 2021-11-18 Amgen Inc. Methods of identifying attributes of therapeutic proteins

Also Published As

Publication number Publication date
TW202308690A (zh) 2023-03-01
JP2024517418A (ja) 2024-04-22
JOP20230265A1 (ar) 2023-10-22
PE20240068A1 (es) 2024-01-11
CR20230531A (es) 2024-01-08
AR125408A1 (es) 2023-07-12
MX2023012363A (es) 2023-11-01
CO2023014181A2 (es) 2023-10-30
EP4326766A1 (en) 2024-02-28
CL2023003155A1 (es) 2024-04-19
CN117203233A (zh) 2023-12-08
BR112023021867A2 (pt) 2023-12-19
WO2022226339A9 (en) 2023-08-24
CA3216655A1 (en) 2022-10-27
UY39736A (es) 2022-10-31
WO2022226339A1 (en) 2022-10-27
US20240190951A1 (en) 2024-06-13
IL307540A (en) 2023-12-01
AU2022262421A1 (en) 2023-10-19

Similar Documents

Publication Publication Date Title
KR20240000537A (ko) 항-tslp 항체 조성물 및 이의 용도
EP3277722B1 (en) Antibodies to canine interleukin-4 receptor alpha
KR20230028453A (ko) 치료 용도를 위한 ccr8 항체
JP2020156506A (ja) 抗ｉｌ−３６ｒ抗体
CA3166949A1 (en) Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2)
KR20220127378A (ko) 안정한 항-ｉｆｎａｒ1 제형
KR20230175245A (ko) 변형된 항-tslp 항체
KR20190053184A (ko) 아토피성 피부염을 치료하기 위한 il-13 길항제의 용도
TW201615663A (zh) 抗ｉｌ－１３／ｉｌ－１７雙特異性抗體及其用途
TW201518321A (zh) 抗－ｉｌ－４抗體及雙特異性抗體及其用途
US20190359701A1 (en) Methods of treating diseases
TW202108621A (zh) 抗-sema3a抗體及其用於治療眼或眼部疾病之用途
HUE028615T2 (en) Treatment of osteoarthritis
AU2023315149A1 (en) Bispecific anti-c-kit and anti-cd203c antigen-binding molecules and uses thereof
KR20240102971A (ko) 모수네투주맙을 이용하여 전신 홍반성 루푸스(sle)를 치료하기 위한 방법과 조성물
CN112384535A (zh) 用于治疗慢性荨麻疹的方法和组合物
WO2022061032A1 (en) Methods and compositions for treating viral infection
AU2021369929A1 (en) Use of an il-18 antagonist for treating and/or prevention of atopic dermatitis or a related condition
WO2024092064A1 (en) Anti-tslp antibody compositions and uses thereof
CN118401549A (zh) 人ngf的犬源化和猫源化抗体
EA045206B1 (ru) Способы и композиции для лечения аллергических заболеваний глаз

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20231116

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250418

Comment text: Request for Examination of Application